ELI LILLY & CoLLY
時価総額
$1兆
PER
医薬品の研究開発・製造・販売の米国最大手。GLP-1系抗肥満薬や糖尿病薬、バイオ医薬品を含む製品群を展開。2023年12月にPOINTを約10.4億ドルで買収、2024年5月にウィスコンシンの製造施設を約9.25億ドルで買収。米国・欧州・日本・中国を中心に世界展開。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net income | 5,070 | 4,348 | 4,089 | 4,685 | 2,391 | 2,408 | 2,738 | -204 | 3,232 | 8,318 | 6,194 | 5,582 | 6,245 | 5,240 | 10,590 |
| Depreciation and amortization | 1,328 | 1,374 | 1,462 | 1,446 | 1,379 | 1,428 | 1,497 | 1,567 | 1,609 | 1,233 | 1,324 | 1,548 | 1,523 | 1,527 | 1,767 |
| Change in deferred income taxes | - | 269 | -126 | -286 | 36 | 748 | -439 | 788 | -327 | -62 | 135 | 802 | 2,185 | 2,341 | 2,683 |
| Stock-based compensation expense | 231 | 147 | 142 | 145 | 156 | 218 | 255 | 281 | 280 | 312 | 308 | 343 | 371 | 629 | 646 |
| Investment (gains) losses, net | - | - | - | - | - | - | - | - | - | - | 1,439 | 178 | -420 | -23 | -50 |
| Gains on sale of product rights | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,879 | 224 |
| Acquired in-process research and development | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,800 | 3,280 |
| Other operating activities, net | - | -18 | 121 | 25 | 241 | 36 | 380 | 442 | 472 | 349 | 334 | 511 | 305 | 296 | 777 |
| Receivables—(increase) decrease | -319 | 189 | -362 | 153 | -117 | 305 | 709 | 357 | 997 | 127 | 1,350 | 1,278 | 300 | 2,451 | 2,155 |
| Inventories—(increase) decrease | 157 | -203 | 308 | 287 | 307 | 736 | 328 | 254 | -8 | 259 | 533 | 236 | 600 | 1,425 | 2,507 |
| Prepaid expenses and other assets—(increase) decrease | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,331 |
| Accounts payable and other liabilities—increase (decrease) | -364 | 591 | -336 | -70 | -261 | 462 | 819 | 916 | -284 | -478 | 1,271 | -664 | 1,332 | 4,274 | 2,609 |
| Net Cash Provided by Operating Activities | 6,857 | 7,235 | 5,305 | 5,735 | 4,367 | 2,773 | 4,851 | 5,616 | 5,525 | 4,837 | 6,500 | 7,261 | 7,084 | 4,240 | 8,818 |
| Purchases of property and equipment | 694 | 672 | 905 | 1,012 | 1,163 | 1,066 | 1,037 | 1,077 | 1,211 | 1,034 | 1,388 | 1,310 | 1,854 | 3,448 | 5,058 |
| Proceeds from Sale of Short-Term Investments | - | - | - | 3,320 | 4,054 | 2,162 | 1,642 | 4,853 | 2,553 | 137 | 130 | 47 | 121 | 192 | 149 |
| Purchases of short-term investments | - | - | - | - | - | - | - | - | - | 43 | 11 | 84 | 107 | 98 | 99 |
| Proceeds from Sale and Maturity of Other Investments | 585 | 2,139 | 4,356 | 11,235 | 11,009 | 3,068 | 2,086 | 2,586 | 3,510 | 610 | 757 | 800 | 342 | 508 | 374 |
| Purchases of noncurrent investments | 1,067 | 4,459 | 7,619 | 14,042 | 9,803 | 3,227 | 4,346 | 4,612 | 838 | 248 | 359 | 930 | 600 | 731 | 677 |
| Proceeds from sale of product rights | - | - | 1,212 | - | - | - | - | - | - | - | - | - | - | 1,604 | 601 |
| Purchases of in-process research and development | - | - | - | - | 95 | 560 | 55 | 1,087 | 1,808 | - | - | - | - | 3,945 | 3,346 |
| Cash paid for acquisitions, net of cash acquired | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,044 | 948 |
| Other investing activities, net | 219 | 112 | 101 | 97 | 25 | 134 | 130 | 216 | 191 | 249 | -103 | -24 | 206 | 192 | 298 |
| Net Cash Used for Investing Activities | -3,160 | -4,824 | -2,833 | -2,073 | -3,909 | 27 | -3,139 | -3,784 | 1,906 | -8,083 | -2,259 | -2,762 | -3,262 | -7,153 | -9,301 |
| Dividends paid | 2,165 | 2,180 | 2,187 | 2,121 | 2,101 | 2,127 | 2,159 | 2,192 | 2,312 | 2,410 | 2,687 | 3,087 | 3,536 | 4,069 | 4,680 |
| Net change in short-term borrowings | 124 | -141 | -10 | - | 2,681 | -2,681 | 1,293 | 1,398 | -2,198 | 995 | -1,494 | -4 | 1,498 | 4,691 | -1,852 |
| Proceeds from issuance of long-term debt | 1 | - | - | - | 993 | 4,455 | 1,207 | 2,232 | 2,480 | 6,556 | 2,062 | 2,411 | - | 3,959 | 11,417 |
| Repayments of long-term debt | 1 | 55 | 1,501 | 11 | 1,035 | 1,956 | 0 | 631 | 1,009 | 2,866 | 277 | 1,905 | 1,560 | - | 664 |
| Purchases of common stock | - | - | 721 | 1,698 | 800 | 750 | 600 | 300 | 4,151 | 4,400 | 500 | 1,250 | 1,500 | 750 | 2,500 |
| Other financing activities, net | 19 | 6 | - | - | 187 | 139 | -301 | -364 | -373 | -200 | -242 | -296 | -309 | -335 | -491 |
| Net Cash Provided by (Used for) Financing Activities | -2,022 | -2,370 | -4,420 | -3,829 | -75 | -2,919 | -560 | 143 | -5,905 | -2,324 | -3,137 | -4,131 | -5,407 | 3,496 | 1,230 |
| Effect of exchange rate changes on cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | 216 | -206 | -168 | 169 | -297 |
| Net increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | 1,320 | 161 | -1,751 | 752 | 450 |